These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28506912)

  • 1. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2017 Aug; 809():163-171. PubMed ID: 28506912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Switching From Another Sodium-Glucose Cotransporter 2 Inhibitor to Tofogliflozin on Nocturia in Patients With Type 2 Diabetes.
    Inoue S; Yasuda H; Yoshida K; Mori K; Ogawa K; Yokotsuka Y; Okamoto H
    Cureus; 2024 Apr; 16(4):e59411. PubMed ID: 38826603
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Kong J; Li L; Yuan H; Bai F; Yang K; Zhao L; Xu S
    J Biomol Struct Dyn; 2023; 41(17):8109-8120. PubMed ID: 36200619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology.
    May M; Framke T; Junker B; Framme C; Pielen A; Schindler C
    Ther Adv Endocrinol Metab; 2019; 10():2042018819891886. PubMed ID: 31853361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Current understanding of complications associated with diabetes.
    Srivastava SP
    Front Clin Diabetes Healthc; 2023; 4():1338656. PubMed ID: 38125705
    [No Abstract]   [Full Text] [Related]  

  • 6. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
    Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
    Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target.
    Di Franco A; Cantini G; Tani A; Coppini R; Zecchi-Orlandini S; Raimondi L; Luconi M; Mannucci E
    Int J Cardiol; 2017 Sep; 243():86-90. PubMed ID: 28526540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data.
    Yanai H; Hakoshima M; Adachi H; Kawaguchi A; Waragai Y; Harigae T; Masui Y; Kakuta K; Hamasaki H; Katsuyama H; Kaga T; Sako A
    J Clin Med Res; 2017 Jul; 9(7):605-612. PubMed ID: 28611861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Budoff MJ; Wilding JPH
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMPA-REG OUTCOME: The Nephrologist's Point of View.
    Wanner C
    Am J Med; 2017 Jun; 130(6S):S63-S72. PubMed ID: 28526179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
    Kawanami D; Matoba K; Takeda Y; Nagai Y; Akamine T; Yokota T; Sango K; Utsunomiya K
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease.
    Mosleh W; Sharma A; Sidhu MS; Page B; Sharma UC; Farkouh ME
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):311-318. PubMed ID: 28536852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
    Osonoi T; Nakamoto S; Saito M; Tamasawa A; Ishida H; Osonoi Y
    J Diabetes Investig; 2018 Mar; 9(2):341-353. PubMed ID: 28644562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
    J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study.
    Fukuda T; Bouchi R; Terashima M; Sasahara Y; Asakawa M; Takeuchi T; Nakano Y; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Diabetes Ther; 2017 Aug; 8(4):851-861. PubMed ID: 28616806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.
    Lee G; Oh SW; Hwang SS; Yoon JW; Kang S; Joh HK; Kwon H; Kim J; Park D
    PLoS One; 2017; 12(5):e0177646. PubMed ID: 28542373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
    Xu L; Nagata N; Nagashimada M; Zhuge F; Ni Y; Chen G; Mayoux E; Kaneko S; Ota T
    EBioMedicine; 2017 Jun; 20():137-149. PubMed ID: 28579299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.